|
1
|
Michalek IM, Loring B and John SM: A
systematic review of worldwide epidemiology of psoriasis. J Eur
Acad Dermatol Venereol. 31:205–212. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Batani A, Brănișteanu DE, Ilie MA, Boda D,
Ianosi S, Ianosi G and Caruntu C: Assessment of dermal papillary
and microvascular parameters in psoriasis vulgaris using in
vivo reflectance confocal microscopy. Exp Ther Med.
15:1241–1246. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Caruntu C, Boda D, Căruntu A, Rotaru M,
Baderca F and Zurac S: In vivo imaging techniques for psoriatic
lesions. Rom J Morphol Embryol. 55 (3 Suppl):S1191–S1196.
2014.PubMed/NCBI
|
|
4
|
Dlova NC and Mosam A: Inflammatory
noninfectious dermatoses of HIV. Dermatol Clin. 24439–448.
(VI)2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mamkin I, Mamkin A and Ramanan SV:
HIV-associated psoriasis. Lancet Infect Dis. 7(496)2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Jordaan HF: Common skin and mucosal
disorders in HIV/AIDS. S Afr Fam Pract. 50:14–23. 2008.
|
|
7
|
Cedeno-Laurent F, Gómez-Flores M, Mendez
N, Ancer-Rodríguez J, Bryant JL, Gaspari AA and Trujillo JR: New
insights into HIV-1-primary skin disorders. J Int AIDS Soc.
14(5)2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fife DJ, Waller JM, Jeffes EW and Koo JY:
Unraveling the paradoxes of HIV-associated psoriasis: A review of
T-cell subsets and cytokine profiles. Dermatol Online J.
13(4)2007.PubMed/NCBI
|
|
9
|
Friedrich M, Krammig S, Henze M, Döcke WD,
Sterry W and Asadullah K: Flow cytometric characterization of
lesional T cells in psoriasis: Intracellular cytokine and surface
antigen expression indicates an activated, memory/effector type 1
immunophenotype. Arch Dermatol Res. 292:519–521. 2000.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mallon E and Bunker CB: HIV-associated
psoriasis. AIDS Patient Care STDS. 14:239–246. 2000.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Niculet E, Radaschin DS, Nastase F,
Draganescu M, Baroiu L, Miulescu M, Arbune M and Tatu AL: Influence
of phytochemicals in induced psoriasis (review). Exp Ther Med.
20:3421–3424. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cheaito MA, Khalifeh M, Jaafar B and Rizk
N: Immune reconstitution inflammatory syndrome presenting as
psoriasis after initiating antiretroviral therapy: A case-report. J
Infect Dis Ther. 6(387)2018.
|
|
13
|
Saketkoo LA and Espinoza LR: Impact of
biologic agents on infectious diseases. Infect Dis Clin North Am.
20:931–961, viii. 2006.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Boda D, Negrei C, Nicolescu F and Badalau
C: Assessment of some oxidative stress parameters in methotrexate
treated psoriasis patients. Farmacia. 62:704–710. 2014.
|
|
15
|
Caruntu C, Boda D, Dumitrascu G,
Constantin C and Neagu M: Proteomics focusing on immune markers in
psoriatic arthritis. Biomark Med. 9:513–528. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Teh YC, Robinson S, Tan WC, Kwan Z and
Tang MM: Psoriasis patients with human immunodeficiency virus
infection: Data from the malaysian psoriasis registry. Malaysian J
Dermatol. 46:1–10. 2021.
|
|
17
|
Warren RB, Weatherhead SC, Smith CH, Exton
LS, Mohd Mustapa MF, Kirby B and Yesudian PD: British association
of dermatologists' guidelines for the safe and effective
prescribing of methotrexate for skin disease 2016. Br J Dermatol.
175:23–44. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ezhilarasan D: Hepatotoxic potentials of
methotrexate: Understanding the possible toxicological molecular
mechanisms. Toxicology. 458(152840)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kaushik SB and Lebwohl MG: Psoriasis:
Which therapy for which patient: Focus on special populations and
chronic infections. J Am Acad Dermatol. 80:43–53. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Queirós N and Torres T: HIV-associated
psoriasis. Actas Dermosifiliogr (Engl Ed). 109:303–311.
2018.PubMed/NCBI View Article : Google Scholar : (In English,
Spanish).
|
|
21
|
Gallitano SM, McDermott L, Brar K and
Lowenstein E: Use of tumor necrosis factor (TNF) inhibitors in
patients with HIV/AIDS. J Am Acad Dermatol. 74:974–980.
2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Bardazzi F, Magnano M, Campanati A,
Loconsole F, Carpentieri A, Potenza C, Bernardini N, Di Lernia V,
Carrera C, Raone B, et al: Biologic therapies in HIV-infected
patients with psoriasis: An Italian experience. Acta Derm Venereol.
97:989–990. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lambert JLW, Segaert S, Ghislain PD,
Hillary T, Nikkels A, Willaert F, Lambert J and Speeckaert R:
Practical recommendations for systemic treatment in psoriasis in
case of coexisting inflammatory, neurologic, infectious or
malignant disorders (BETA-PSO: Belgian evidence-based treatment
advice in psoriasis; part 2). J Eur Acad Dermatol Venereol.
34:1914–1923. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Esposito M, Carubbi F, Giunta A, Alunno A,
Giacomelli R and Fargnoli MC: Certolizumab pegol for the treatment
of psoriatic arthritis and plaque psoriasis. Expert Rev Clin
Immunol. 16:119–128. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Yang K, Oak ASW and Elewski BE: Use of
IL-23 inhibitors for the treatment of plaque psoriasis and
psoriatic arthritis: A comprehensive review. Am J Clin Dermatol.
22:173–192. 2021.PubMed/NCBI View Article : Google Scholar
|
